DETERMINE Precision Medicine
DETERMINE is the first UK national precision medicine trial in rare cancers, testing a range of therapies specifically targeting key genetic changes in cancer cells.
DETERMINE is led by the University of Manchester and is sponsored and managed by Cancer Research UK's Centre for Drug Development. It is run in collaboration with the University of Birmingham, the Royal Marsden NHS Foundation Trust and the Christie NHS Foundation Trust.
Meet our investigators
Dr Matthew Krebs
Chief Investigator
University of Manchester
Dr Krebs is a medical oncologist with expertise in precision medicine. He is responsible for the medical, scientific and strategic oversight of the DETERMINE platform. He is also the Chief Investigator of the TARGET Precision Medicine program, which is a major route for patent identification for DETERMINE.
Paediatric Lead
Royal Marsden Hospital
Dr Marshall is a paediatric oncologist with expertise in drug development. She is responsible for overseeing the medical and scientific aspects of the DETERMINE study with respect to children and young people.
Find out more
Translational Lead
University of Birmingham
Professor Middleton is a medical oncologist with expertise in the genomic, transcriptomic and immunological context underlying response to targeted therapy. He is Translational Lead for the DETERMINE study and will coordinate academic research at the Universities of Manchester and Birmingham and the Institute of Cancer Research.
Find out more
Statistical Lead
University of Birmingham
Professor Billingham is a biostatistician with an interest in cancer research. She is responsible for the design and statistical analysis of the DETERMINE study.
Find out more
Adult participant sites
England
- Manchester: The Christie Hospital - Adult- OPEN
- Oxford: Churchill Hospital - Adult- OPEN
- Cambridge: Addenbrookes Hospital - Adult - OPEN
- Newcastle upon Tyne: Freeman Hospital - Adult- OPEN
- Birmingham: University Hospital -Adult-OPEN
- Leicester: Leicester Royal Infirmary - Adult -OPEN
- London: Guy's Hospital - Adult -OPEN
- London: University College London Hospital - Adult -OPEN
- Bristol: Haematology and Oncology Cancer Centre - Adult -OPEN
- Sheffield: Weston Park Hospital - Adult -OPEN
- Liverpool- Adult- OPEN
- Southampton- Adult- OPEN
Wales
- Cardiff: Velindre Cancer Centre- Adult- OPEN
Scotland
- Edinburgh: Western General Hospital - Adult- OPEN
- Glasgow: The Beatson Cancer Centre - Adult- OPEN
Northern Ireland
- Belfast: Health and Social Care Trust - Adult- OPEN
Paediatric participant sites
England
- Cambridge: Addenbrookes Hospital - Paediatric, teenagers and young adults- OPEN
- Newcastle upon Tyne: Great North Children Hospital -Paediatric, teenagers and young adults- OPEN
- Oxford: John Radcliffe Hospital- Paediatric, teenagers and young adults- OPEN
- Bristol: The Bristol Royal Hospital for children- Paediatric, teenagers and young adults-OPEN
- Liverpool: Alder Hey -Paediatric, teenagers and young adults-OPEN
- London/Surrey: Royal Marsden Hospital -Paediatric, teenagers and young adults- OPEN
- London: Great Ormond Street Hospital- Paediatric, teenagers and young adults- OPEN
- Sheffield: Sheffield Children Hospital-Paediatric, teenagers and young adults- OPEN
- Manchester- in set up
Wales
- Cardiff- in set up
Scotland
- Glasgow: The Royal Hospital for children Glasgow- Paediatric, teenagers and young adults- OPEN
Northern Ireland
- Coming soon
Related information
Centre for Drug Development
The Cancer Research UK Centre for Drug Development (CDD) translates today's science into tomorrow's medicine. With over 100 scientists and operational staff, we are the partner of choice for pre-clinical and early phase drug development.
Cancer Chat
Cancer Chat is Cancer Research UK's fully moderated forum where you can talk to others affected by cancer, share experiences, and get support.
Cancer Chat is free to join and available 24 hours a day.